ALLARITY ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm

Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business and operations during the class period from May 17, 2022, to July 19, 2024 [1][3]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York on behalf of all individuals and entities who purchased Allarity securities during the specified class period [1]. - Investors have until November 12, 2024, to apply to be appointed as lead plaintiff in the lawsuit [1]. Allegations Against the Company - The complaint alleges that Allarity and its former officers overstated the regulatory prospects of the Dovitinib NDA [3]. - It is claimed that the company engaged in illegal and improper conduct related to the Dovitinib NDA and Dovitinib-DRP PMA [3]. - The misconduct allegedly increased the risk of regulatory scrutiny and enforcement actions, leading to potential legal, monetary, and reputational harm [3]. - Following the announcement of an investigation into wrongdoing, the company reportedly downplayed the likelihood of enforcement actions resulting from the investigation [3]. - As a result, the company's public statements were deemed materially false and misleading throughout the class period [3].